# OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

> **NCT00064428** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12092 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **DRUG:** fondaparinux - UFH not indicated
- **OTHER:** Control - UFH not indicated
- **DRUG:** Fondaparinux - UFH indicated
- **DRUG:** Control - UFH

## Key facts

- **NCT ID:** NCT00064428
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 12092 (ACTUAL)
- **Last updated:** 2016-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064428, "OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00064428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*